Hypoxia is a common feature of many solid tumors and contributes to their progression. Hypoxic tumor cells are resistant to conventional chemotherapy and radiotherapy and hypoxia promotes a more malignant phenotype.
Hypoxia-inducible factor-1 (HIF-1) is a central mediator of cellular responses to low oxygen and has recently become an important therapeutic target for solid tumor therapy. HIF-1 is overexpressed in common cancers and their metastases, including the prostate, breast, colon, and lung cancers.
2) HIF-1 is a heterodimeric transcription factor composed of HIF-1a and HIF-1b. HIF-1b, also known as the aryl hydrocarbon receptor nuclear translocator, is constitutively present in normoxic cells. In contrast, the HIF-1a levels are primarily dependent on the intracellular oxygen concentration.
3) Under normoxic conditions, the HIF-1a protein is hydroxylated by prolyl hydroxylases which require oxygen for activity, and then rapidly and continuously degraded by ubiquitination and proteasomal degradation. 4, 5) Once hydroxylated, HIF-1a rapidly binds to pVHL, a negative regulator of HIF-1 that directs it for proteasomal degradation through its E3 ubiquitin ligase activity. 6, 7) HIF-1 targets the transcription of over 60 genes important for the adaptation and survival under hypoxia. 8) The vascular endothelial growth factor (VEGF) is a major transcriptional target of HIF-1 and one of the most important factors that stimulate angiogenesis in solid tumors, diabetic retinopathy, and rheumatoid arthritis. 9, 10) We previously established a high through-put assay system using a stable transformant of mammalian cells that expressed the luciferase gene under the control of the hypoxiaresponse element. 11) To identify novel HIF-1 pathway inhibitors, we screened 5000 cultured broths of microorganisms using this system, and found that cinerubin showed a significant inhibition of reporter activity induced by hypoxic conditions. In this paper, we describe the effects of anthracycline antibiotics on the HIF-1 pathway.
MATERIALS AND METHODS

Cell Lines and Reagents
A stable transformant of CHO cells was established by the transfection of the HIF-1-dependent luciferase (5ϫHRE/pGL3/VEGF/E1b) and neomycin resistant genes as previously described.
11) Stably transfected cells were maintained in a-MEM supplemented with 10% fetal bovine serum (ICN Biomedicals, Costa Mesa, CA, U.S.A.) and kanamycin (50 mg/ml). The HepG2 human hepatoma cells were maintained in RPMI1640 with 10% fetal bovine serum and kanamycin (50 mg/ml). Cells were cultured at 37°C in a humidified incubator containing 5% CO 2 (normoxia). Hypoxic treatment was performed by incubating cells at 37°C in an air-tight chamber (Forma Scientific Inc., Marietta, OH, U.S.A.) filled with a mixture of 90% N 2 , 5% CO 2 and 5% H 2 . Cinerubin was isolated from Streptomyces. Doxorubicin, aclarubicin and daunorubicin were purchased from Sigma Aldrich Japan. All reagents were initially dissolved in DMSO (sigma) and diluted with the medium for assay.
Reporter Gene Assay Stably transfected cells were seeded at 1ϫ10 4 cells/well in 96-well microplates 1 d before the following treatment. They were treated with drugs for 15 h under hypoxic conditions, and then harvested for determination of the luciferase activity. The assay was carried out using the Luciferase Assay System from Promega.
Western Blotting Treated cells were washed with icecold PBS containing 0.1 mM Na 3 VO 4 and then lysed in a lysis buffer (20 mM HEPES, 150 mM NaCl, 1% Triton X-100, 10% Glycerol, 1 mM EDTA, 50 mM NaF, 50 mM b-glycerophosphate, 1 mM Na 3 VO 4 and 25 mg/ml each of antipain, leupeptin, and pepstatin). The protein concentration of the lysates was determined using a Protein Assay Kit (Bio-Rad, Hercules, CA, U.S.A. Hypoxia-inducible factor-1 (HIF-1) is a central mediator of cellular responses to low oxygen and has recently become an important therapeutic target for solid tumor therapy. To identify small molecule inhibitors of the HIF-1 transcriptional activation, we have established a high through-put assay system using a stable transformant of mammalian cells that express the luciferase reporter gene construct containing a HIF-1 binding site. Using this system, we screened 5000 cultured broths of microorganisms, and we found that cinerubin (1-hydroxy aclacinomycin B) showed a significant inhibition of the reporter activity induced by hypoxic conditions. In addition, we demonstrated that aclarubicin also inhibited the HIF-1 transcriptional activity under hypoxic conditions, but neither doxorubicin nor daunorubicin inhibited it. Consistent with these results, cinerubin and aclarubicin inhibited the hypoxic induction of the vascular endothelial growth factor (VEGF) protein in HepG2 cells, but neither doxorubicin nor daunorubicin affected it. Thus, our results suggested that some anthracyclines are also acting as angiogenesis inhibitors.
Bedford, MA, U.S.A.). The membranes were blocked for 1 h at room temperature with blocking buffer and then incubated with primary antibodies specific for HIF-1a (1 : 200 dilution, BD Bioscience) or b-actin (1 : 5000 dilution, Sigma Aldrich Japan). The membranes were then washed and chemiluminescence detection was performed using peroxidase-conjugated secondary antibodies.
RT-PCR The total RNA from the HepG2 cells was isolated using RNeasy (Qiagen K. K., Tokyo, Japan). The cDNAs were synthesized using AMV reverse transcriptase (Promega, Madison, WI, U.S.A.) with the same quantity of RNA (1 mg) and amplified using the Taq DNA polymerase (Promega, Madison, WI, U.S.A.). The following primers were used: human HIF-1a, sense, 5Ј-AACGACAAGAAAAAGATAA-GTTCT-3Ј; antisense, 5Ј-GTTGGTTACTGTTGGTATCATA-3Ј; human VEGF, sense, 5Ј-GGATGTCTATCAGCGCAG-CTAC; antisense, 5Ј-TCACCGCCTCGGCTTGTCACATC. The conditions for amplification were as follows: 94°C for 2 min followed by 30 cycles of 94°C for 30 s, 55°C for 30 s, 72°C for 1 min in a TAKARA PCR Thermal Cycler MP (Takara Bio, Shiga, Japan). After amplification, the products were electrophoresed in a 2% agarose gel and detected by ethidium bromide.
Northern Blotting For Northern blotting, total RNA was extracted with guanidium-hot phenol and samples of 20 mg of RNA per lane were separated on agarose gel containing 2.2 M formamide. The RNA was transferred to a nylon membrane and hybridized with a probe labeled by nick translation as described previously.
12) The probes were prepared by a reverse transcription-polymerase chain reaction (RT-PCR) method using total RNA from HUVEC as a template and primers (5Ј-GAGTGTGTGCCCACTGAGGAG-TCCAAC and 5Ј-CTCCTGCCCGGCTCACCGCCTCGG-CTT) for VEGF, and (5Ј-GTAGTGCTGACCCTGCACTC-AA and 5Ј-TCCATCGGAAGGACTAGGTGTC) for HIF1a, and DNA fragments were cloned in a pGEM-T Easy vector. Glyceraldehyde phosphate dehydrogenase (GAPDH) cDNA was used as a reference.
12)
ELISA HepG2 cells were seeded at 1ϫ10 4 cells/well in 96-well microplates 1 d before the following treatment. Supernatants were collected from the HepG2 cells after 15 h of drug treatment under the indicated conditions. The total levels of the VEGF protein were measured using the Human VEGF Colorimetric ELISA Kit (PIERCE ENDOGEN, Rockford, IL, U.S.A.).
RESULTS
Effect of Anthracyclines on the Expression of VEGF Promoter Reporter Gene
To identify the novel small molecules targeting the HIF-1 pathway, we transfected Chinese hamster ovary (CHO) cells with a luciferase reporter gene construct containing 5 copies of a HIF-1 binding site derived from the human VEGF promoter and established a stable clone. We screened 5000 cultured broths of microorganisms using this stable clone, and we found that cinerubin, an anthracycline antibiotic, showed a significant inhibition of the reporter activity induced by hypoxic conditions.
To study the effect of other anthracyclines on the HIF-1 transcriptional activity, we examined the inhibitory effects of the clinical chemotherapy drugs, doxorubicin, aclarubicin and daunorubicin.
As shown in Fig. 1 , the luciferase activity was significantly induced (60-fold) in response to hypoxia, whereas no induction was seen in the cells with the empty vector (data not shown). The hypoxic induction of luciferase activity was significantly inhibited by cinerubin and aclarubicin in a dosedependent manner under hypoxic conditions with IC 50 values of 0.016 and 0.021 mg/ml, respectively. In contrast, neither doxorubicin nor daunorubicin inhibited the luciferase activity. These anthracyclines did not show any cytotoxic effects at the concentrations used in this experiment. The 50% inhibitory concentrations on stable transformant proliferation (48-h exposure assay) were determined as 0.08, 0.05, 0.22 and 0.20 mg/ml in cinerubin, aclarubicin, doxorubicin and daunorubicin, respectively.
Cinerubin Reduces HIF-1a a Protein Expression But Not HIF-1a a mRNA Expression in HepG2 Cells To test whether the inhibition of the HIF-1 activity by cinerubin is caused by the decrease in the HIF-1a protein, HepG2 cells were treated with cinerubin and doxorubicin, and the protein levels of HIF-1a were measured by Western blot. As shown in Fig. 2A , the hypoxic incubation induced HIF-1a protein accumulation, but cinerubin decreased the hypoxic induction of the HIF-1a protein. In contrast, doxorubicin did not affect hypoxic induction of HIF-1a protein.
We then examined the effect of cinerubin on the HIF-1a mRNA expression by RT-PCR. As shown in Fig. 2B , the HIF-1a mRNA levels did not change by the addition of cinerubin.
These experiments indicated that cinerubin did not transcriptionally affect the HIF-1a, but it decreased the HIF-1a protein accumulation.
Cinerubin Reduces VEGF mRNA Expression in HepG2 Cells HIF-1 activates the transcription of many target genes important for survival under hypoxia, and VEGF is a major transcriptional target of HIF-1. To assess whether or not cinerubin inhibits the VEGF expression, we analyzed the effect of cinerubin on the VEGF mRNA level by RT-PCR in the HepG2 cells. As shown in Fig. 3A , cinerubin decreased hypoxic induction of the VEGF mRNA expression. Similar results were obtained by Northern blot experiments (Fig.  3B) . In contrast, doxorubicin caused a little decrease in the VEGF mRNA at 3.0 mg/ml.
Cinerubin Reduces VEGF Protein Expression in HepG2 Cells
To determine whether cinerubin inhibits the VEGF protein expression, we analyzed the effect of cinerubin on the VEGF protein level in the HepG2 Cells by ELISA analysis. As shown in Fig. 4A , cinerubin dramatically inhibited the production of VEGF. Aclarubicin also showed a dose-dependent inhibitory effect, while neither doxorubicin nor daunorubicin showed it. DISCUSSION HIF-1 is essential for angiogenesis and tumor progression, and thus it is an attractive molecular target for cancer therapy. To identify small molecule inhibitors of the HIF-1 transcriptional activation, we have established a high through-put assay system using a stable transformant of mammalian cells that express the luciferase reporter gene construct containing a HIF-1 binding site.
This study showed that cinerubin (1-hydroxy aclacinomycin B) significantly inhibited the HIF-1 activity. Cinerubin is an anthracycline antibiotic that potentially inhibits the proliferation of a wide variety of tumor cell lines, but it is not in clinical use. Therefore, we examined the inhibitory effects of other clinically used anthracyclines, including doxorubicin, aclarubicin and daunorubicin.
Interestingly, the hypoxic induction of luciferase activity was significantly inhibited by aclarubicin, but doxorubicin and daunorubicin did not inhibit it under hypoxic conditions (Fig. 1) . Moreover, these anthracycline compounds did not inhibit androgen receptor transactivation of the PSA promoter gene (data not shown).
Consistent with HIF-1 reporter assay, cinerubin and aclarubicin inhibited the hypoxic induction of the VEGF protein in the HepG2 cells, but neither doxorubicin nor daunorubicin inhibited it (Fig. 4) .
Cinerubin reduced the HIF-1a protein expression, but it did not affect the HIF-1a mRNA expression in the HepG2 cells (Fig. 2) . These results suggest the possibility that cinerubin has an effect on degradation or translation of the HIF-1a protein. Rapisarda et al. have recently shown that topotecan, a topoisomerase I poison, inhibits the HIF-1a protein accumulation independently of the DNA replication-mediated DNA damage, suggesting a distinct mechanism of action from the cytotoxic effects.
13) It is known that anthracyclines are also topoisomerase II poisons. Although doxorubicin and daunorubicin mediate their cytotoxicity by poisoning the enzyme topoisomerase II, aclarubicin has been hypothesized to inhibit the catalytic action of topoisomerase II. 14) Besides this activity, aclarubicin has been reported to exert a concomitant poisoning effect on topoisomerase I. 15) Our results suggest that there is an unknown pathway connecting topoisomerase I to the HIF-1a protein accumulation independent of the DNA damage.
In conclusion our results suggested that some anthracyclines are also acting as inhibitors of angiogenesis.
